Xbrane Biopharma AB (publ)

OM:XBRANE Stock Report

Market Cap: SEK 245.9m

Xbrane Biopharma Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of XBRANE?
Owner TypeNumber of SharesOwnership Percentage
Private Companies1,970,9890.129%
Individual Insiders32,752,0022.14%
Institutions115,703,0647.56%
General Public1,379,057,34290.2%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 5044.4%.

Top Shareholders

Top 25 shareholders own 11.75% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
4.7%
Nordnet AB (publ), Asset Management Arm
71,877,720SEK 11.6m0%0.16%
3.76%
Avanza Fonder AB
57,489,493SEK 9.2m0%0.01%
1.83%
Bengt Westman
28,005,559SEK 4.5m0%no data
0.5%
SEB Investment Management AB
7,596,042SEK 1.2m0%no data
0.2%
Ashkan Pouya
3,120,298SEK 501.7k0%no data
0.12%
Storebrand Fonder AB,
1,831,206SEK 294.5k0%no data
0.1%
Nidda Healthcare Holding GmbH
1,570,989SEK 252.6k0%no data
0.093%
Teknik Innovation Norden Fonder AB
1,415,055SEK 227.5k0%0.01%
0.092%
Futur Pension Försäkringsaktiebolag, Asset Management Arm
1,408,825SEK 226.5k0%0.01%
0.085%
Swedbank Robur Fonder AB
1,306,172SEK 210.0k0%no data
0.074%
Hakan Stodberg
1,136,448SEK 182.7k0%no data
0.074%
Skandia Fonder AB
1,133,253SEK 182.2k0%no data
0.032%
Handelsbanken Asset Management
482,144SEK 77.5k0%no data
0.026%
Obadja AB
400,000SEK 64.3k0%no data
0.023%
Nordnet Pensionsförsäkring Ab, Asset Management Arm
345,324SEK 55.5k0%no data
0.012%
Martin Amark
189,280SEK 30.4k0%no data
0.0076%
Siavash Bashiri
116,502SEK 18.7k0%no data
0.0051%
FCG Fonder AB
77,860SEK 12.5k0%no data
0.0046%
Anders Tullgren
70,484SEK 11.3k0%no data
0.0044%
Danske Bank A/S, Asset Management Arm
66,657SEK 10.7k0%no data
0.0037%
Cicero Fonder AB
56,154SEK 9.0k0%no data
0.0022%
David Vikström
33,153SEK 5.3k0%no data
0.0017%
Karin Wingstrand
25,480SEK 4.1k0%no data
0.00098%
Anette Lindqvist
15,003SEK 2.4k0%no data
0.00098%
Peter Edman
15,000SEK 2.4k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/30 05:36
End of Day Share Price 2024/12/30 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Xbrane Biopharma AB (publ) is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John SavinEdison Investment Research
Hans MählerNordea Markets
null nullNordea Markets